Market Newsdesk

New York, N.Y., March 25, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it has assembled the first reactor core hardware of its ZEUS microreactor for initial non-nuclear testing.

ZEUS, a solid core battery reactor, is being developed by NANO Nuclear as part of the next generation of portable, on-demand capable, advanced nuclear microreactors to provide clean, scalable power for data centers, remote locations, industrial sites, military operations, and disaster relief scenarios. The successful validation of the reactor core through scaled testing will position NANO Nuclear to advance toward full prototype construction and licensing efforts in the coming years.

The assembled hardware consists of a 1:2 scale block, precisely engineered to be representative of a fuel element of the ZEUS microreactor core. This milestone represents a major advancement in NANO Nuclear’s continued development of its proprietary microreactor technology.

The initial testing phase will focus on the assessment of the thermo-mechanical performance of the block under anticipated prototypical conditions for ZEUS. The results will inform the next stages of reactor development. These results will be crucial for verifying engineering plans, refining physics models, and optimizing ZEUS core and heat management systems.

Figure 1 – NANO Nuclear Energy Inc.’s fuel element being set up for testing.

“We are very excited to have completed the first ZEUS reactor core block for non-nuclear testing,” said Prof. Peter Hosemann, Head of Nuclear Reactor Design and Materials of NANO Nuclear. “This very precise component will be heated conventionally using linear heaters as fuel rod surrogates. The test will be used to verify temperature distribution, to investigate fit tolerances, and to confirm and benchmark our models, paving the way for a larger sub-core assembly.”

“I am thrilled to see our transition from design to hardware assembling and testing for a key component of our ZEUS reactor,” said Prof. Massimiliano Fratoni, Senior Director and Head of Reactor Design of NANO Nuclear. “The lack of an in-core fluid in our ZEUS design not only simplifies greatly the design but also enables rapid prototyping and non-nuclear testing. We are expecting to iterate quickly through progressively larger scale tests up to full core.”

Figure 2 – Single core block fully outfitted with linear heaters as fuel rod surrogates (left image) Infrared camera image of the block during initial test (right image).

NANO Nuclear’s engineering team is preparing to mount insulation, fixtures, and instrumentation to create a single-block demonstration unit, which will eventually scale up to a fully functional demo core assembly. In the next phase, the team will integrate cabling, sensors, and additional structural components to build a fully instrumented demo unit. This will enable the team to gather essential data on heat transfer, material performance, and overall reactor safety margins, facilitating real-world validation of the ZEUS reactor’s thermal and structural performance and ensuring that the design meets expectations before full-scale assembly.

“Achieving this hardware milestone represents a major step forward in our ZEUS microreactor program,” said James Walker, Chief Executive Officer of NANO Nuclear. “This testing will provide our team with the key thermal and mechanical insights needed to fine-tune the core design before full-scale fabrication and regulatory engagement.”

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include patented KRONOS MMR^™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission in collaboration with University of Illinois Urbana-Champaign, “ZEUS”, a portable solid core battery reactor, “ODIN”, a portable low-pressure coolant reactor, and the space focused, portable LOKI MMR^™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR^™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:

Email: [email protected]
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:

NANO Nuclear Energy LINKEDIN

NANO Nuclear Energy YOUTUBE

NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This news release and statements of NANO Nuclear’s management in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. In this press release, forward-looking statements includes those related to the timing for and results of the ZEUS testing described herein, as well as the overall timing and anticipated steps for ZEUS development. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy (“DOE”) or related state or non-U.S. nuclear fuel licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE and the U.S. Nuclear Regulatory Commission, including those associated with the recently enacted ADVANCE Act, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Attachment

• NANO Nuclear Energy Inc.

CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced the integration of Geotab’s advanced telematics technology into its Workhorse W56 step van. This offering combines active data monitoring in the W56 with Geotab solutions to seamlessly integrate vehicle data into the MyGeotab™ platform. Fleet managers can now access vital vehicle data through a unified dashboard, enhancing fleet performance and mobility.

With the integration into the Workhorse W56, accessing Geotab’s technology is now a plug-and-play experience, enabling fleets to reduce costs, maximize uptime, and increase efficiency.

“Geotab is committed to optimizing fleet performance, especially for fleets transitioning to electric vehicles,” said Bobby Valentine, Head of Global OEM Strategic Partnerships at Geotab. “By integrating our technology with Workhorse vehicles, we offer vital insights to streamline charging schedules and optimize battery usage. This ensures operational efficiency and cost savings throughout the transition, and beyond.”

The Workhorse W56 is designed to be the ideal zero-emission vehicle for last-mile delivery. With its impressive range, substantial cargo capacity, and proven performance, the W56 meets the demanding needs of modern delivery operations. When paired with Geotab’s advanced telematics, fleet managers gain the tools they need to track and optimize their vehicles, making operations smoother and more efficient. By choosing to equip their W56 step vans with Geotab’s telematics technology, fleet managers can fully leverage EV efficiencies.

“By partnering with Geotab, we are offering access to one of the most widely deployed analytics tools for fleets worldwide,” said Josh Anderson, CTO of Workhorse. “With over 4 million connected vehicles globally, including a significant number of medium-duty fleets in the U.S., Geotab’s reach is unmatched. This integration allows us to provide our customers with top-tier products that enhance efficiency, reduce downtime, and maximize the benefits of electric vehicle technology.”

About Workhorse Group Inc.

Workhorse Group Inc. (Nasdaq: WKHS) is a technology company focused on pioneering the transition to zero-emission commercial vehicles. Workhorse designs and builds its vehicles in the United States at the Workhorse Ranch in Union City, Indiana. The company’s best-in-class vehicles are designed for last-mile delivery, medium-duty operations, and a growing range of specialized applications. For more information, visit www.workhorse.com.

About Geotab

Geotab is a global leader in connected vehicle and asset solutions, empowering fleet efficiency and management. We leverage advanced data analytics and AI to transform fleet performance, safety, and sustainability, reducing cost and driving efficiency. Backed by top data scientists and engineers, we serve over 55,000 global customers, processing 80 billion data points daily from more than 4.7 million vehicle subscriptions. Geotab is trusted by Fortune 500 organizations, mid-sized fleets, and the largest public sector fleets in the world, including the US Federal Government. Committed to data security and privacy, we hold FIPS 140-3 and FedRAMP authorizations. Our open platform, ecosystem of outstanding partners, and Marketplace deliver hundreds of fleet-ready third-party solutions. This year, we’re celebrating 25 years of innovation. Learn more at www.geotab.com and follow us on LinkedIn or visit Geotab News and Views.

Forward-Looking Statements

The discussions in this press release contain forward-looking statements reflecting our current expectations that involve risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “expect,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements and relate to future periods. These are statements that involve substantial risks and uncertainties, including our ability to timely deliver the W56 step vans applicable to the purchase order and conditions to delivery and acceptance thereof. Forward-looking statements are statements that are not historical facts and speak only as of the date hereof. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

Media Contact:

Aaron Palash / Greg Klassen
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Investor Relations Contact:

Tom Colton and Greg Bradbury
Gateway Group
949-574-3860
[email protected]

Quadruple Digit % Gains Year-Over-Year and Triple Digit % Gains Quarter-Over-Quarter Reflected in 2024 Form


10-K

Debt-Free and $13.50 Cash Value Per Common Share*

Increased Growth Projected For Q1 2025

LAS VEGAS and LOS ALAMITOS, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), Transforming the Landscape of Social Commerce, Social Telehealth and Social Crowdfunding with MARKET.live; VANITYPrescribed; GoodGirlRx; and the GO FUND YOURSELF TV Show, today filed its Form 10-K reporting financial and operating results for the full year and the quarter ending December 31, 2024.

Summary Financial Results

For the Year Ended December 31, 2024

• Total revenue was $895 thousand, an increase of $832 thousand, or 1,321%, over the previous year. Represents the greatest amount of revenue generated since the strategic sale of the Company’s direct sales SaaS business unit in June 2023
• Cash Value per common share – $13.4 (*includes value of highly-liquid professionally managed investments)
• *Year-End Cash position $13.5 million ($8.5 million cash, plus $4.9 million in highly-liquid investments). Does not include $1.7 million cash added in Q1 2025.
• Strong Cash Position – expected to fund operations into 2028 and beyond
• Net loss from continuing operations reduced by $4.3 million, represents an improvement of 29% over prior year
• Operating loss reduced by $2.2 million, represents an improvement of 16% over prior year
• General and Administrative expenses reduced by $0.3 million, represents an improvement of 2% over prior year, indicates enhanced Company financial performance attributable to increases in revenue – not excessive cost cutting measures
• All Remaining Debt retired in Q1 2025

Three Months Ended December 31, 2024

• Total Q4 revenue – $723 thousand, an increase of $694 thousand, or 2,393%, from the prior year comparable quarter – represents an increase of $595 thousand, or 465% over Q3. Indicates enormous revenue growth in Q4 attributable to management’s recent operational and marketing changes which are further validated by projected Q1 2025 results.

Results of Operations

Fiscal Year Ended December 31, 2024 Compared to Fiscal Year Ended December 31, 2023

The following is a comparison of the results of our operations for the years ended December 31, 2024 and 2023 (in thousands):

		Years Ended December 31,
		2024				2023				Change
Revenue		$	895			$	63			$	832
Costs and expenses
Cost of revenue, exclusive of depreciation and amortization shown separately below			224				19				205
Depreciation and amortization			1,077				2,331				(1,254	)
General and administrative			11,238				11,508				(270	)
Total costs and expenses			12,539				13,858				(1,319	)
Operating loss from continuing operations			(11,644	)			(13,795	)			2,151
Other income (expense)
Interest income			692				–				692
Unrealized loss on short-term investments			(44	)			–				(44	)
Interest expense			(237	)			(1,193	)			956
Financing costs			(90	)			(1,239	)			1,149
Other income, net			812				1,162				(350	)
Change in fair value of derivative liability			1				221				(220	)
Total other income (expense), net			1,134				(1,049	)			2,183
Net loss from continuing operations		$	(10,510	)		$	(14,844	)		$	4,334

Revenue

Revenue was $895 for the year ended December 31, 2024, as compared to $63 for the year ended December 31, 2023. The revenue increase of $832, representing an increase of 1,321%, is primarily attributable to revenue received from our MARKET.live business unit services packages and from our Go Fund Yourself business unit.

Revenue was $723 for the quarter ended December 31, 2024, as compared to $29 for the quarter ended December 31, 2023. The revenue increase of $694, representing an increase of 2,393%, is primarily attributable to tremendous growth from our MARKET.live business unit services packages and from our newly-formed Go Fund Yourself business unit.

Revenue was $723 for the quarter ended December 31, 2024, as compared to $128 for the quarter ended September 30, 2024. The revenue increase of $595, representing an increase of 465%, is primarily attributable to tremendous growth from our MARKET.live business unit services packages and from growth in our Go Fund Yourself business unit.

The table below sets forth our quarterly revenues from the quarter ended September 30, 2023 (first quarter following the direct sales SaaS sale) through the quarter ended December 31, 2024, which reflects the trend of revenue over the past six fiscal quarters:

Operating Expenses

Depreciation and amortization expense was $1,077 for the year ended December 31, 2024, as compared to $2,331 for the year ended December 31, 2023. The decrease of $1,254 is due to a revision in the amortization of software development costs resulting from extending the life of the asset on January 1, 2024.

General and administrative expenses including stock compensation expense were $11,238 for the year ended December 31, 2024, as compared to $11,508 for the year ended December 31, 2023. The decrease of $270 or 2%, in general and administrative expenses including stock compensation expense is primarily due to a decrease in stock compensation expense and a decrease in legal fees.

Other Income (Expense), net

Other income (expense), net, was $1,134 for the year ended December 31, 2024, which was primarily attributable to other income, net of $812 and interest income, net of $455 both offset by financing costs of $90.

Liquidity and Capital Resources

Overview

As of December 31, 2024 and 2023, we had the following balances of cash, restricted cash, and highly liquid investments.

			As of December 31,
			2024				2023
Cash		$	7,617			$	4,353
Restricted Cash			878				–
Investments: Government-Backed Securities			3,731				–
Investments: Corporate Bonds			1,182				–
Total			13,408				4,353

Subsequent to December 31, 2024, we received $1,724 of our ERC short-term receivable.

Conference Call Information

VERB CEO, Rory J. Cutaia will hold a conference call today, March 25, 2025, at 1:00 p.m. Eastern time to discuss the 2024 results and strategic plans for 2025. A telephonic replay of the conference call is available from 4:00 p.m. Eastern time today through April 8, 2025.

VERB Q4 and FY 2024 Earnings Call

Date: Tuesday, March 25, 2025
Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time)

To access by phone: Please call the conference telephone number 10-15 minutes prior to the start time. An operator will register your name and organization.

Meeting Link:
CLICK HERE

Toll Free: 1-877-407-4018
Toll/International: 1-201-689-8471
Telephonic Replay: Available after 4:00 p.m. Eastern time on the same day through Tuesday, April 8, 2025 at 11:59 PM ET

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13752553

About VERB

Verb Technology Company, Inc. (Nasdaq: VERB), is the innovative force behind interactive video-based social commerce. The Company operates three business units, each of which leverages its social commerce technology and video marketing expertise. The Company’s MARKET.live platform is a multi-vendor, livestream social shopping destination at the forefront of the convergence of e-commerce and entertainment, where brands, retailers, creators, and influencers engage their customers, clients, fans, and followers across multiple social media channels simultaneously. GO FUND YOURSELF is a revolutionary interactive social crowd funding platform and TV show for public and private companies seeking broad-based exposure across social media channels for their crowd-funded Regulation CF and Regulation A offerings. The platform combines a ground-breaking interactive TV show with MARKET.live’s back-end capabilities allowing viewers to tap, scan or click on their screen to facilitate an investment, in real time, as they watch companies presenting before the show’s panel of “Titans”. Presenting companies that sell consumer products are able to offer their products directly to viewers during the show in real time through shoppable onscreen icons. VANITYPrescribed.com and GoodGirlRx.com are telehealth portals, intended to redefine telehealth by offering a seamless, digital-first experience that empowers individuals to take control of their healthcare needs. They were designed and developed to disrupt the traditional healthcare model by providing tailored healthcare solutions at affordable, fixed prices – without hidden fees, membership costs, or inflated pharmaceutical markups. GoodGirlRx.com, a partnership with Savannah Chrisley, a well-known lifestyle personality and advocate for health and wellness, offers customers access to convenient, no-hassle telehealth services and pharmaceuticals, including the new weight-loss drugs, with fixed pricing regardless of dosage, breaking away from the industry’s traditional model of excessive pricing and pharmaceutical gatekeeping.

The Company is headquartered in Las Vegas, NV and operates full-service production and creator studios in Los Alamitos, California.

For more information, please visit: www.verb.tech

Follow VERB and MARKET.live here:

VERB on Facebook: https://www.facebook.com/VerbTechCo
VERB on Twitter: https://twitter.com/VerbTech_Co
VERB on LinkedIn: https://www.linkedin.com/company/verb-tech
VERB on YouTube: https://www.youtube.com/channel/UC0eCb_fwQlwEG3ywHDJ4_KQ

Sign up for E-mail Alerts here: https://ir.verb.tech/news-events/email-alerts

FORWARD-LOOKING STATEMENTS

This communication contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties and include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, or achievements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those identified in our filings with the Securities and Exchange Commission (the “SEC”), including our annual, quarterly and current reports filed with the SEC and the risk factors included in our annual report on Form 10-K filed with the SEC today. Any forward-looking statement made by us herein is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

[email protected]

Media Contact:

[email protected]

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/98fa0d86-9d94-4cfa-97f5-ffd4c89edad9

https://www.globenewswire.com/NewsRoom/AttachmentNg/c013f2c6-3f17-4624-bd9a-60b7c28ab5fe

HOUSTON, March 25, 2025 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leader in advanced energy management platforms, today announced it has increased its bitcoin purchases for its Bitcoin Treasury by an additional $5 million to reach a total of $65 million in bitcoin acquisitions. The additional purchases were made at a weighted average price of $88,824 per bitcoin, inclusive of fees and expenses. The Company now holds 668.3 BTC.

This strategic move aligns with KULR’s Bitcoin Treasury Strategy announced on December 4, 2024, wherein the Company committed up to 90% of its surplus cash reserves to be held in bitcoin.

BTC Yield as a Key Performance Indicator

Year to date, KULR has achieved a BTC Yield of 181.1%, leveraging a combination of surplus cash and its At-The-Market (ATM) equity program to fund purchases.

KULR uses “BTC Yield” as a key performance indicator (KPI) for its Bitcoin Treasury strategy. BTC Yield is calculated as the percentage change period-to-period in the ratio of the Company’s bitcoin holdings to its Assumed Fully Diluted Shares Outstanding. This KPI helps assess the effectiveness of KULR’s bitcoin acquisition strategy in a manner KULR believes drives shareholder value.

Important Considerations Regarding BTC Yield

BTC Yield is intended to provide insights into KULR’s bitcoin acquisition strategy but should not be interpreted as a measure of operating performance, financial return, or liquidity. It is not equivalent to traditional yield metrics, nor does it account for the Company’s liabilities or broader financial position.

The trading price of KULR’s common stock is influenced by multiple factors beyond bitcoin holdings, and BTC Yield does not predict or reflect the stock’s market value. Investors should consider this metric as a supplementary tool and refer to the Company’s financial statements and SEC filings for additional information about the Company’s financial position.

KULR remains committed to its strategic goals of advancing shareholder value while adhering to disciplined financial management.

For additional details, please visit www.kulrtechnology.com.

No Offer or Solicitation

This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of KULR Technology Group Inc., nor shall there be any offer, solicitation or sale of such securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About KULR Technology Group Inc.

KULR Technology Group Inc. (NYSE American: KULR) delivers cutting edge energy storage solutions for space, aerospace, and defense by leveraging a foundation of in-house battery design expertise, comprehensive cell and battery testing suite, and battery fabrication and production capabilities. The Company’s holistic offering allows delivery of commercial-off-the-shelf and custom next generation energy storage systems in rapid timelines for a fraction of the cost compared to traditional programs. On December 4, 2024, KULR announced that its Board of Directors has agreed to include bitcoin as a primary asset in its treasury program and committed to allocating up to 90% of its surplus cash to the acquisition of bitcoin. For more information, please visit www.kulrtechnology.com.

Safe Harbor Statement   
This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on April 12, 2024, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely based on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.  

Investor Relations:

KULR Technology Group, Inc.
Phone: 858-866-8478 x 847
Email: [email protected]

FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and decontamination solutions, today announced an OEM partnership with Pharma Biotech System Components LLC/Pharma Biotech System Components Ltd (PBSC), a premier manufacturer specializing in high containment, material decontamination, and cleanroom solutions. This collaboration enhances TOMI’s SteraMist Integrated System (SIS) product launched in the second half of last year. Through this OEM agreement, TOMI will now offer pass-through hatches and chambers integrated with iHP, specifically designed for optimized decontamination cycles.

PBSC is one of the leading manufacturers of Cleanroom, High Containment, and Material Decontamination products worldwide, offering an extensive product range, bespoke designs, and assembly capabilities. Catering to the needs of customers with high-quality products and services within the Pharmaceutical, Medical Research, high Containment, and Hospital sectors around the world.

This partnership enables TOMI to leverage PBSC’s expertise in high-containment enclosures while expanding the adoption of SteraMist in critical industries. Through integration with PBSC’s designs, TOMI’s SIS provides an efficient method for achieving high-level disinfection in critical environments. Several projects are currently underway, showcasing the strong market demand for this innovative system.

“We are excited to formalize our partnership with PBSC,” said Elissa J. (E.J.) Shane, COO of TOMI Environmental Solutions. “This agreement represents a significant advancement in fulfilling the increasing demand for iHP-integrated disinfection solutions. We are experiencing strong interest and are actively marketing and bidding on projects utilizing SIS products and high-quality pass-through hatches and chambers offered by PBSC.”

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.

For additional information, please visit http://www.steramist.com or contact us at [email protected]

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products to serve life science sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
[email protected]

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (TSX Venture: PTK; NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced it plans to demonstrate its latest technology innovations and products at the Optical Fiber Communications (OFC) Conference, which will be held in San Francisco, California from April 1st to April 3rd, 2025. POET’s executive management team and engineers will be meeting customers and industry analysts at the Company’s booth No. 5315 during the Exhibition.

POET Blazar™ Demo (Invitation Only): Senior technical and executive management of select technology companies will have the opportunity to observe the highly anticipated POET Blazar prototype in private meetings with POET management. Built on the POET Optical Interposer™ platform, Blazar is a ground-breaking light source solution to power both co-packaged optics (CPO) and high-bandwidth, chip-to-chip, light-based data communications links. Named after an extremely bright galactic object, Blazar utilizes POET’s wafer-level chip-scale packaging technology to create a high-power, multi-channel light source as an alternative to traditional DFB laser-based solutions. Wafer-level chip-scale technology significantly lowers the cost of the light source, provides larger scale and better reliability, and promises to increase the effective supply of Indium Phosphide, a rare and limited compound semiconductor material commonly used as the light-producing element in lasers. 

“Given the vast potential of our ELS (external light source) solution and the sensitive nature of the technology, we have opted to limit its exposure, which is why we are selecting a number of senior technologists and executives to an invitation-only viewing,” POET Chairman and CEO Dr. Suresh Venkatesan said. “The Blazar can transform the economies of scale for AI connectivity with an architecture that reduces costs and increases scale and manufacturing efficiency. With the massive amount of compute power that AI demands, we believe that the Blazar offers an economically superior solution to achieving next-generation performance. It is a crucial component to getting to 3.2T in pluggable optical modules and achieving the higher speeds, bandwidth and low-latency needed for chip-to-chip data communication links.”

POET Teralight™ 1.6T Optical Engine (Live Public Demo): In partnership with Mitsubishi Electric, POET will unveil its Teralight product line of 1.6T highly integrated transmit and receive optical engines offering a complete optical system-on-chip architecture that reduces cost and simplifies module design. The 1.6T transmit engine includes only four externally modulated laser chips, rather than the standard eight lasers for 1.6T transceivers, due to Mitsubishi Electric’s unique 2x200G EML laser design, a cost reduction in the most expensive transmit component. Built-in high-speed drivers, monitor photo diodes, a thermistor and optical multiplexers (for FR4 applications) make this the most highly integrated system-on-chip available on the market. The receive engine includes photo diodes, trans-impedance amplifiers (TIAs) and demultiplexers (for FR4 applications). The POET Optical Interposer design eliminates the use of wire bonds between devices, which reduces the RF crosstalk to achieve industry-leading performance at the highest speeds available on the market. The system-on-chip architecture allows customers to use the same board design for 1.6T DR8 and 2xFR4 pluggable modules, a feature unique to POET that eliminates the need for separate DR and FR engineering teams, which has been a standard development approach within the industry.

Leading Module Customers Incorporating POET Optical Engines: Among the leading suppliers offering modules based on POET’s optical engines, LuxshareTech will be demonstrating 400G and 800G DR and FR modules at OFC (Booth #4905) and Adtran (formerly ADVA) will demo a highly integrated Quattro 100G LR4 in their private demo room. Quattro LR4 integrates four instances of 100G LR4 into a single QSFP-DD form factor, quadrupling the density of 100G ports in 400G switch and routing platforms. This module has gained intense interest from both hyperscalers and telecom network providers for its performance and cost-effectiveness.

Product Showcase: POET will also have a product showcase of its current portfolio suite of optical engines and light sources at its booth. Some of those products have been designed into customer solutions that will be demonstrated at the POET booth as market-ready applications.

Lightwave Award: In addition, Company representatives will collect the recently announced Elite Score award at the Lightwave+BTR Innovations Reviews Reception, which is scheduled to be held at the Moscone Center in Rooms 307/308 on March 31, 2025 at 5:00 PM PST.

About POET Technologies Inc.

POET is a design and development company offering high-speed optical modules, optical engines and light source products to the artificial intelligence systems market and to hyperscale data centers. POET’s photonic integration solutions are based on the POET Optical Interposer™, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using advanced wafer-level semiconductor manufacturing techniques. POET’s Optical Interposer-based products are lower cost, consume less power than comparable products, are smaller in size and are readily scalable to high production volumes. In addition to providing high-speed (800G, 1.6T and above) optical engines and optical modules for AI clusters and hyperscale data centers, POET has designed and produced novel light source products for chip-to-chip data communication within and between AI servers, the next frontier for solving bandwidth and latency problems in AI systems. POET’s Optical Interposer platform also solves device integration challenges in 5G networks, machine-to-machine communication, self-contained “Edge” computing applications and sensing applications, such as LIDAR systems for autonomous vehicles. POET is headquartered in Toronto, Canada, with operations in Allentown, PA, Shenzhen, China, and Singapore. More information about POET is available on our website at www.poet-technologies.com.

Media Relations Contact: Adrian Brijbassi [email protected]	Company Contact: Thomas R. Mika, EVP & CFO [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products, including with the Blazar light source and 1.6T optical engines featured in today’s announcement, and expectations regarding its successful development of high speed transceiver solutions and its penetration of the Artificial Intelligence hardware markets.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, the completion of its development efforts with its customers, the ability to build working prototypes to the customer’s specifications, and the size, future growth and needs of Artificial Intelligence network suppliers. Actual results could differ materially due to a number of factors, including, without limitation, the failure to demonstrate the Blazar light source a 1.6T optical engines at the upcoming OFC Conference, failure to produce optical engines on time and within budget, the failure of Artificial Intelligence networks to continue to grow as expected, the failure of the Company’s products to meet performance requirements for AI and datacom networks, operational risks in the completion of the Company’s projects, the ability of the Company to generate sales for its products, including those in today’s announcement, and the ability of its customers to deploy systems that incorporate the Company’s products. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7d68dcbe-ead9-40e0-82ba-ddc1a655791c

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025

Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025

$22.8 million in cash and cash equivalents as of December 31, 2024

DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

“We made excellent progress across our pipeline in 2024, laying a strong foundation for the year ahead,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “We continue to enroll patients in the ACESOT-1051 trial evaluating our WEE1 kinase inhibitor, APR-1051, which we believe has best in class potential. The compound appears safe and well tolerated to date with no hematologic toxicity. We look forward to reporting open label data from ACESOT-1051 in the second half of the year. We are also advancing ATRN-119, our highly selective first-in-class macrocyclic ATR inhibitor. The ongoing ABOYA-119 trial is now evaluating ATRN-119 as continuous once daily and twice daily monotherapy in order to maximize therapeutic benefit. Our ultimate goal is to transform the treatment paradigm for difficult to treat cancers by unlocking the full potential of DDR-based therapies.”

Key Business Updates and Potential Upcoming Key Milestones

ACESOT-1051: A Biomarkers Focused, Phase 1 Trial of Oral WEE1 inhibitor, APR-1051

• APR-1051 is a potent and selective small molecule that has been designed to potentially solve tolerability challenges of the WEE1 class and may achieve greater clinical activity than other programs currently in development. Aprea is advancing APR-1051 as monotherapy in cancers with Cyclin E over-expression, as well as other biomarkers that may predict sensitivity to WEE1 inhibition. Cancers over-expressing Cyclin E represent a high unmet medical need. Patients with Cyclin E over-expression have poor prognosis and, currently, have no effective therapies available.
• Patients are now being enrolled in Cohort 5 (70 mg dose) of the ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) trial. This Phase 1 clinical trial is evaluating single-agent APR-1051 in advanced solid tumors harboring cancer-associated gene alterations. No hematological toxicities have been observed to date. The primary objectives of the Phase 1 study are to measure safety, dose-limiting toxicities (DLTs), maximum tolerated dose or maximum administered dose (MTD/MAD), and recommended Phase 2 dose (RP2D); secondary objectives are to evaluate pharmacokinetics and preliminary efficacy according to RECIST or PCWG3 criteria; pharmacodynamic parameters are exploratory objectives.
• In October 2024, preliminary findings from the ACESOT-1051 trial were reported in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain. The poster can be viewed on Aprea’s corporate website here.
• Preliminary efficacy data from ACESOT-1051 are expected in the second half of 2025. For more information, refer to ClinicalTrials.gov NCT06260514.

ABOYA-119: Ongoing Clinical Trial Evaluating ATR inhibitor, ATRN-119

• ATRN-119 is a potent and highly selective first-in-class macrocyclic ATR inhibitor, designed to be used in patients with mutations in DDR-related genes. Cancers with mutations in DDR-related genes represent a high unmet medical need. Patients with DDR-related gene mutations have a poor prognosis and, currently, there are no effective therapies available for them.
• ATRN-119 is being evaluated in the open-label Phase 1/2a clinical trial of ABOYA-119 as monotherapy in patients with advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. Patients are currently being enrolled at Dose Level 7, with both 1100 mg once daily and 550 mg twice daily doses being evaluated independently and in parallel. The addition of twice daily dosing was implemented to potentially optimize ATRN-119’s activity across a 24-hour cycle thereby providing better target coverage and maximal clinical benefit. This is expected to increase the likelihood of achieving superior clinical outcomes and may potentially accelerate the path to regulatory approval and commercialization. 
• An update from the ABOYA-119 trial was provided in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October, 2024. A copy of the poster can be viewed here.
• For more information on ABOYA-119, please refer to clinicaltrials.gov NCT04905914. 

Corporate

• Aprea engaged Philippe Pultar, MD in October 2024 as senior medical advisor to support the development and advancement of APR-1051. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology. He was most recently employed at Zentalis Pharmaceuticals where he played a key role in the strategy and execution of the global clinical development of azenosertib, a WEE1 inhibitor.

Select Financial Results for the Fourth Quarter ended December 31, 2024

• For the quarter ended December 31, 2024, the Company reported an operating loss of $3.2 million, compared to an operating loss of $3.7 million in the fourth quarter of 2023.
• Research and Development (R&D) expenses were $2.4 million for the quarter ended December 31, 2024, compared to $2.0 million for the fourth quarter of 2023. The increase in R&D expense was primarily related to an increase in personnel costs primarily related to new hires and severance.
• General and Administrative (G&A) expenses were $1.1 million for the quarter ended December 31, 2024, compared to $1.6 million for the comparable period in 2023.
• The Company reported a net loss of $2.9 million ($0.49 per basic share) on approximately 6.0 million weighted-average common shares outstanding for the quarter ended December 31, 2024, compared to a net loss of $3.4 million ($0.92 per basic share) on approximately 3.7 million weighted average common shares outstanding for the comparable period in 2023.

Select Financial Results for the Year ended December 31, 2024

• As of December 31, 2024, the Company reported cash and cash equivalents of $22.8 million compared to $21.6 million as of December 31, 2023. The Company believes its cash and cash equivalents as of December 31, 2024 will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the first quarter of 2026.
• For the year ended December 31, 2024, the Company reported an operating loss of $14.3 million, compared to an operating loss of $15.5 million for the year ended December 31, 2023.
• R&D expenses were $9.4 million for the year ended December 31, 2024, compared to $7.6 million for the year ended December 31, 2023. The increase in R&D expense was primarily related to the ABOYA-119 clinical trial to evaluate ATRN-119, the initiation of the ACESOT-1051 clinical trial to evaluate APR-1051 and an increase in personnel costs primarily related to new hires and severance.
• G&A expenses were $6.5 million for the year ended December 31, 2024, compared to $8.4 million for the year ended December 31, 2023. The decrease in G&A expenses was primarily due to a decrease in personnel costs primarily related to severance expense for former executives and insurance premiums.
• The Company reported a net loss of $13.0 million ($2.35 per basic share) on approximately 5.5 million weighted-average common shares outstanding for the year ended December 31, 2024, compared to a net loss of $14.3 million ($3.95 per basic share) on approximately 3.6 million weighted average common shares outstanding for the comparable period in 2023.

About Aprea

Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement


Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:

Mike Moyer
LifeSci Advisors
[email protected]

Aprea Therapeutics, Inc.
Consolidated Balance Sheets
		December 31,				December 31,
		2024				2023
Assets
Current assets:
Cash and cash equivalents		$	22,849,885			$	21,606,820
Prepaid expenses and other current assets			726,254				914,275
Total current assets			23,576,139				22,521,095
Property and equipment, net			81,522				88,362
Restricted cash			40,170				40,717
Other noncurrent assets			281,662				—
Total assets		$	23,979,493			$	22,650,174
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	1,352,240			$	1,670,369
Accrued expenses			2,008,735				2,186,262
Deferred revenue			—				528,974
Total current liabilities			3,360,975				4,385,605
Commitments and contingencies
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively.			1,311,063				1,311,063
Stockholders’ equity:
Common stock, $0.001 par value, 400,000,000 shares authorized, 5,481,055 and 3,736,673 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively.			5,481				3,736
Additional paid-in capital			350,971,225				335,644,204
Accumulated other comprehensive loss			(10,627,379	)			(10,611,273	)
Accumulated deficit			(321,041,872	)			(308,083,161	)
Total stockholders’ equity			19,307,455				16,953,506
Total liabilities and stockholders’ equity		$	23,979,493			$	22,650,174

Aprea Therapeutics, Inc.
Consolidated Statements of Operations and Comprehensive Loss
		Three Months Ended December 31,								Year Ended December 31,
		2024				2023				2024				2023
		(Unaudited)
Grant revenue		$	205,817			$	14,075				1,502,581			$	583,231
Operating expenses:
Research and development			2,359,086				2,045,689			$	9,363,537			$	7,627,491
General and administrative			1,072,776				1,643,315				6,458,699			$	8,427,703
Total operating expenses			3,431,862				3,689,004				15,822,236				16,055,194
Loss from operations			(3,226,045	)			(3,674,929	)			(14,319,655	)			(15,471,963	)
Other income (expense):
Interest income, net			274,626				310,287				1,289,144			$	1,224,133
Foreign currency gain (loss)			56,620				(78,612	)			71,800			$	(38,926	)
Total other income			331,246				231,675				1,360,944				1,185,207
Net loss		$	(2,894,799	)		$	(3,443,254	)		$	(12,958,711	)		$	(14,286,756	)
Other comprehensive (loss) income :
Foreign currency translation			(22,632	)			24,601				(16,106	)		$	12,135
Total comprehensive loss			(2,917,431	)			(3,418,653	)		$	(12,974,817	)		$	(14,274,621	)
Net loss per share attributable to common stockholders, basic and diluted		$	(0.49	)		$	(0.92	)		$	(2.35	)		$	(3.95	)
Weighted-average common shares outstanding, basic and diluted			5,954,700				3,736,673				5,509,921			$	3,617,607

–  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%.

–  Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging between 24% to 29.2%.

–  Data are supportive of Olvi-Vec being a platinum resensitizing agent beyond ovarian cancer and, consistent with earlier studies, being systemically administered in multiple solid tumor types which underscore the current clinical development strategy.

–  Olvi-Vec was generally well-tolerated with a favorable safety profile. Participant enrollment into dose escalation cohorts continues to investigate safety and the recommended intravenous dose of Olvi-Vec for the Phase 2 trial.

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, and Newsoara BioPharma Co., Ltd., a pre-commercial-stage biopharmaceutical company, today announced preliminary safety and anti-tumor activity data from the dose escalation Phase 1b portion of the companies’ co-sponsored ongoing Phase 1b/2 clinical trial (OLVI-VEC-SCLC-202) of Olvi-Vec immunochemotherapy in patients with platinum-relapsed or platinum-refractory extensive small cell lung cancer.

“We are encouraged by the Phase 1b trial data which suggests preliminary anti-tumor activity. Consistent reductions in all individual target lesions in participants experiencing disease control (5/7), combined with encouraging anti-tumor activity of the first evaluable participant in the most recent dose-escalation cohort, highlights the potential of systemically administered Olvi-Vec to provide meaningful clinical benefit for patients with relapsed or refractory extensive small cell lung cancer,” said Thomas Zindrick, President, CEO, and Chairman of Genelux. “These results are consistent with our previous Phase 2 results in platinum-resistant/refractory ovarian cancer and, with further investigation in our ongoing trials in relapsed/refractory lung cancer, we anticipate demonstrating the potential of Olvi-Vec as a platinum resensitizing immunotherapeutic agent across multiple types of recurrent cancers with significant unmet medical needs.”

Preliminary Dose Escalation Results Update

The primary objectives of this trial are to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of systemically administered Olvi-Vec in the target population. The data cutoff for this announcement was February 19, 2025, with enrollment currently ongoing. Genelux anticipates providing updates on the trial’s progress as it continues to advance, whether through future publications or conference presentations.

Key findings from the ongoing Phase 1b trial include:

Favorable Safety and Tolerability Profile:

• Systemic administration of Olvi-Vec via intravenous delivery demonstrated a manageable safety and tolerability profile, consistent with previous findings in other clinical studies of the investigational immunochemotherapy. Treatment-related adverse events were mostly mild to moderate, including fever, anemia, reduced lymphocyte counts, and nausea. No maximum tolerated dose has been reached to date.

Antitumor Activity:

• Preliminary evidence indicates anti-tumor effect from Olvi-Vec immunochemotherapy. Five of the seven (71%) evaluable participants for anti-tumor response achieved disease control as the best response. The five participants with disease control showed reductions in all of their individual target lesions. All seven evaluable participants had documented disease progression at baseline before joining this study.
• Of the five participants with disease control, two participants exhibited a partial response according to RECIST 1.1. Notably, the first participant in our current dose escalation cohort, who remains on treatment, experienced a tumor reduction of approximately 79%. Additionally, the three remaining participants with disease control, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging from 24% to 29.2%.

“The initial results are promising, especially considering the challenging and fragile nature of this patient population with extensive-stage disease and poor prognosis. What stands out is the anti-tumor responses in these participants, some who have been heavily pre-treated and have failed prior platinum-based therapy, which offers significant potential for Olvi-Vec to provide meaningful clinical benefits in small cell lung cancer, even in a patient population with complex and late-stage disease,” said Dr. Benny Li, CEO of Newsoara. “Ongoing evaluation of the Phase 1b results is consequentially informing the design elements of the Phase 2 portion of the clinical trial.”

About the Olvi-Vec-SCLC-202 Trial

Olvi-Vec-SCLC-202 is a Phase 1b/2, open-label, multicenter clinical trial evaluating the safety, tolerability, pharmacokinetics and efficacy of intravenously delivered Olvi-Vec combined with platinum and etoposide in the treatment of platinum-relapsed or platinum-refractory extensive small cell lung cancer patients. The Phase 1b trial is currently enrolling patients in China at Shanghai Chest Hospital, the lead clinical site, and Zhejiang Provincial People’s Hospital.

Patients receive a single cycle of Olvi-Vec treatment for three consecutive days and, 21 days after the last dose of Olvi-Vec, receive platinum chemotherapy plus etoposide until disease progression or intolerable toxicity occurs.

The dose escalation part of the trial is assessing the safety and tolerability of increasing doses of Olvi-Vec to determine the recommended dose and dosing regimen for Phase 2 expansion. Additionally, safety data may be evaluated to support the potential for Olvi-Vec to be safely combined with other agents, such as an immune checkpoint inhibitor, to further drive deep and durable responses in the Phase 2 portion of the trial.

The Phase 2 portion of the trial is planned to follow and further evaluate the safety and tolerability as well as efficacy of Olvi-Vec at the recommended dose.

About Olvi-Vec

Olvi-Vec (olvimulogene nanivacirepvec), Genelux’s most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec for the treatment of multiple types of cancer based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Genelux granted Newsoara an exclusive license to develop and commercialize Olvi-Vec in greater China (i.e., Mainland China, Hong Kong, Macau and Taiwan). To date, Olvi-Vec has been administered to more than 150 patients in seven completed clinical trials. In these trials, Olvi-Vec was observed to be generally well tolerated with data demonstrating clinical benefit.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. In addition to Olvi-Vec-SCLC-202, Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician’s choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet + physician’s choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. The core of Genelux’s discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.

About Newsoara

Newsoara is a pre-commercial-stage biopharmaceutical company with a mission to develop and commercialize life changing medicines for cancer, autoimmune, metabolic and other major diseases to patients in China and around the world. Since its founding, Newsoara has developed a fully integrated platform which includes R&D, CMC and clinical development capabilities and built a robust and broad pipeline in major therapeutics areas. Newsoara has assembled a world-class management team with extensive experience in innovative drug development that is motivated to improve and impact human health worldwide.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, the potential capabilities, advantages, safety and efficacy of Olvi-Vec to treat small cell lung cancer and other indications and the trial design of the Phase 2 portion of the Phase 1b/2 clinical trial. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Investor and Media Contacts

Ankit Bhargava, MD
Allele Communications, LLC
[email protected]

Source: Genelux Corporation

RISHON LE ZION, Israel, March 25, 2025 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), an integrator of supply chain technologies, announced today that its Supply Chain division has secured a new defense order for $1.2 million for delivery by the third quarter of year 2025.

Avidan Zelicovsky, BOS president, said: “We continue to see increased global defense spending activity at both our primary customers and their subcontractors worldwide, creating new opportunities for BOS. We expect robust ordering patterns across the strategic defense industry to continue in 2025.”

Hagit Eliyahu, Supply Chain division, VP sales, said: “We are pleased to secure yet another new defense industry contract as we continue to build our momentum in 2025.”

About BOS Better Online Solutions Ltd.

BOS integrates cutting-edge technologies to streamline and enhance supply chain operations across three specialized divisions:

• Intelligent Robotics Division: Automates industrial and logistics inventory processes through advanced robotics technologies, improving efficiency and precision.
• RFID Division: Optimizes inventory management with state-of-the-art solutions for marking and tracking, ensuring real-time visibility and control.
• Supply Chain Division: Integrates franchised components directly into customer products, meeting their evolving needs for developing cutting-edge products.

Safe Harbor Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect management’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of BOS. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions, the effect of the war against the Hamas and other parties in the region], the continued availability of financing for working capital purposes and to refinance outstanding indebtedness; and additional risks and uncertainties detailed in BOS’ periodic reports and registration statements filed with the US Securities and Exchange Commission. BOS undertakes no obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

For additional information, contact:

Matt Kreps, Managing Director
Darrow Associates
+1-214-597-8200
[email protected]

Eyal Cohen, CEO
+972-542525925
[email protected]

SECAUCUS, N.J., March 25, 2025 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty retailer in North America with an omni-channel portfolio of brands and an industry-leading digital-first model, today announced that their fourth quarter and year-end fiscal 2024 financial results, and Turki S. AlRajhi’s annual letter to shareholders, will be released on Friday, April 11, 2025 at approximately 4:30 p.m. Eastern Time where it can be accessed at https://corporate.childrensplace.com/.

About The Children’s Place

The Children’s Place is the largest pure-play children’s specialty retailer in North America with an omni-channel portfolio of brands and an industry-leading digital-first model. Its global retail and wholesale network includes two digital storefronts, more than 500 stores in North America, wholesale marketplaces and distribution in 15 countries through six international franchise partners. The Children’s Place designs, contracts to manufacture, and sells fashionable, high-quality, head-to-toe outfits predominantly at value prices. For more information, visit: www.childrensplace.com and www.gymboree.com.

Investor Relations (201) 558-2400 ext. 14500